MD

Medtronic PLCNYSE MDT Stock Report

Last reporting period 25 Oct, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

115.12

Mega

Exchange

XNYS - New York Stock Exchange, Inc

MDT Stock Analysis

MD

Neutral

Based on Eyestock quantitative analysis, MDT`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

61/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-1.5 %

Undervalued

Market cap $B

115.12

Dividend yield

3.11 %

Shares outstanding

1 330.42 B

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. The company is headquartered in Dublin, Dublin and currently employs 95,000 full-time employees. The firm develops, manufactures, and markets its medical devices and technologies to hospitals, physicians, clinicians, and patients. Its operating segments include Cardiovascular, Medical Surgical, Neuroscience and Diabetes. Cardiovascular products include pacemakers, insertable cardiac monitors, and cardiac resynchronization therapy devices. Medical Surgical products include patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications. Neuroscience products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems. Diabetes products include insulin pumps, continuous glucose monitoring (CGM) systems, consumables, and smart insulin pen systems. The company also provides PROPEL and SINUVA. The firm is focused on cardiac ablation portfolio.

View Section: Eyestock Rating